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Introduction: Acinetobacter spp. have emerged as notorious pathogens involved in healthcare-
associated infections. Carbapenems are important antimicrobial agents for treating
infections due to multidrug resistant Acinetobacter spp. Different mechanisms may confer
resistance to these drugs in the genus, particularly production of class D carbapenemases.
OXA-23-like family has been pointed out as one of the predominant carbapenamases among
Acinetobacter. The present work aimed to investigate the occurrence of OXA-23-like car-
bapenemases among Acinetobacter isolates recovered from patients of a university hospital
in Niterói, RJ, Brazil.
Methods: Antimicrobial susceptibility proﬁles were determined by disk-diffusion. Imipenem
resistant isolates were submitted to Modiﬁed Hodge Test in order to screen for carbapene-
mase production, and later to polymerase chain reaction (PCR) to investigate the presence
of blaOXA-23.
Results: Imipenem and meropenem resistance rates were 71.4% and 69.7%, respectively.
The Modiﬁed Hodge Test revealed carbapenemase production among 76 (89.4%) of the 85
imipenem resistant isolates analyzed; according to PCR results, 81 isolates (95.4%) carriedthe blaOXA-23 gene.
Conclusions: OXA-23-like enzymes may be an important mechanism of carbapenem resis-
tance among isolates present in the hospital studied.
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Introduction
Acinetobacter spp. have emerged as one of the most impor-
tant pathogens involved in health care associated infections
in recent decades. These non-fermentative Gram-negative
cocobacilli are frequently involved in the etiology of ventilator-
associated pneumonia, bacteremia, urinary tract infections,
and surgical site infections. These pathogens are also noto-
rious for their ability to accumulate different mechanisms of
antimicrobial resistance, often showing a multidrug-resistant
phenotype.1–4
Carbapenems are considered important antimicrobial
agents for treating infections due tomultidrug-resistant Acine-
tobacter spp. However, reports of resistance to these drugs have
emerged, with increasing frequency, among Acinetobacter spp.
clinical isolates.5–10
Different mechanisms may confer carbapenem resistance
in Acinetobacter spp., but production of carbapenemases is
considered themost important one, particularly those belong-
ing to Ambler’s class D, also known as oxacilinases (OXA).
The class B carbapenemases or metallo--lactamases (MLs)
can also be found among Acinetobacter spp., although less
frequently.11
Five major groups of OXA with carbapenemase activity
have been identiﬁed in Acinetobacter baumannii: acquired OXA-
23-like, OXA-40-like, OXA-58-like, and OXA-143-like families,
and the OXA-51 group, which codiﬁes a chromosomal oxa-
cilinase intrinsic to A. baumannii. When overexpressed, these
enzymes can confer carbapenem resistance.12–17
Among OXA, the variants comprising the OXA-23-like fam-
ily have been detected throughout the world, and have also
been pointed out as the predominant carbapenamases among
Acinetobacter in several geographic regions.
In Brazil, the ﬁrst report of isolates producing these
enzymes were in the city of Curitiba, Paraná.15,18–23 After that
report, Acinetobacter spp. clinical isolates producing OXA-23-
like enzymes have been also identiﬁed in cities like Porto
Alegre-RS, Rio de Janeiro-RJ, Niterói-RJ, São Paulo-SP, Belo
Horizonte-MG, Blumenau-SC, and São Luís-MA.24–31 The OXA-
143-like enzymes, as well as OXA-72 and OXA-58, have also
been found in Brazil.12,16,17,27,32
The present study aimed to investigate the occurrence of
isolates producing the OXA-23-like carbapenemases among
imipenem and/or meropenem-resistant Acinetobacter isolates,
isolated at a university hospital in Niterói, RJ, Brazil.
Material and methods
Bacterial strains
A total of 119 Acinetobacter spp. clinical isolates were studied.
Theywere recovered between July 2007 and July 2009, fromdif-
ferent clinical specimens of 100 patients admitted to Hospital
Universitário Antônio Pedro (HUAP), a 290-bed public tertiary
teaching hospital. Isolates recovered from the same patient
that were isolated from different infection sites, at different
periods of time, or that showed distinct antimicrobial suscep-
tibility proﬁles were included in the study.12;16(6):521–526
The most frequent source of isolation was the inferior
respiratory tract (n=44; 37%), followed by blood (n=28; 23.5%),
urine (n=17; 14.3%), and catheter tip (n=14; 11.8%). Skin and
ascitic ﬂuid isolates corresponded to 5% (n=6) and 2.5% (n=3)
of the entire collection, respectively. Other specimens repre-
sented 4.2% (n=5), whereas two isolates could not have their
origin determined (1.7%). The intensive care unit (ICU) was
the hospital ward that showed the greatest number of isolates
(68/119; 57.1%).
Bacterial strains identiﬁcation
The identiﬁcation of the isolates at the genus level was per-
formed using the VITEK 1 (bioMérieux - Marcy l’Etoile, France)
automated system, at the Microbiology Laboratory of the
Pathology Service of HUAP.
Antimicrobial susceptibility proﬁles
The antimicrobial susceptibility proﬁles of clinical isolates
were determined by disk-diffusion, according to the guide-
lines of the Clinical and Laboratory Standards Institute (CLSI
– 2009).33 The following antimicrobials (CECON – São Paulo,
Brazil) were tested: amikacin (30g), ampicillin/sulbactam
(10g), cefepime (30g), ceftazidime (30g), ciproﬂoxacin
(5g), gentamicin (10g), imipenem (10g), meropenem
(10g), piperacillin/tazobactam, (75mg/10g), sulfamethox-
azole/trimethoprim (23.75/1.25g), ticarcillin/clavulanate
(75/10g), and tetracycline (30g). Escherichia coli ATCC 25922
and Pseudomonas aeruginosa ATCC 27853 were used as quality
control strains.
Phenotypic detection of carbapenemases production
Imipenem resistant (IMP-R) isolates were submitted to Mod-
iﬁed Hodge Test, as described previously by Lee et al. (2001),
with the modiﬁcations indicated bellow.34
The surface of a Mueller-Hinton agar plate was inocu-
lated with a bacterial suspension made of E. coli ATCC 25992
fresh cultures (0.5McFarland turbidity). A 10g imipenemdisk
was placed at the center of the plate. Then, streaks of the
imipenem-resistant isolates were performed from the edge
of the disk to the edge of the plate. The test result was con-
sidered positive if the presence of a distorted inhibition zone
was observed after incubation at 37◦C during 16h to 18h.
Acinetobacter spp. strain A29009 producing OXA-23 was used
as positive control.
Detection of blaOXA-23
All imipenem resistant isolates were investigated by PCR in
order to determine the presence of blaOXA-23, according to
Woodford et al. with the modiﬁcations described below.35
DNA extraction was accomplished by boiling a 3.0 Mc-
Farland turbidity suspension of each isolate for 10minutes.
Then, these suspensions were centrifuged at 8,000 rpm for
2minutes and the supernatant was used as template in PCR
experiments. A 2L volume of DNA template was added to
23L of reactionmixture, which contained 2.5L of PCR buffer
10x (10mM Tris HCl, 25mM KCl), 1mM of MgCl2, 0.5M of
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Table 1 – Antimicrobial susceptibility proﬁle of 119
Acinetobacter spp. clinical isolates recovered between
July 2007 and July 2009, at the Hospital Universitário
Antônio Pedro, in Niterói, RJ, Brazil.
Antimicrobial Resistant
n (%)
Intermediate
n (%)
Sensitive
n (%)
Amikacin 41 (34.5) 8 (6.7) 70 (58.8)
Ampicillin/sulbactam 50 (42) 21 (17.7) 48 (40.3)
Cefepime 98 (82.3) 2 (1.7) 19 (16)
Ceftazidime 92 (77.3) 2 (1.7) 25 (21)
Ciproﬂoxacin 103 (86.6) - 16 (13.4)
Gentamicin 68 (57.1) - 51 (42.9)
Imipenem 85 (71.4) - 34 (28.6)
Meropenem 83 (69.7) - 36 (30.3)
Piperacillin/tazobactam 91 (76.5) 2 (1.7) 26 (21.8)
Sulfamethoxazole/
trimethoprim
94 (79) 4 (3.4) 21 (17.6)
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NTicarcillin/clavulanate 95 (79.8) 2 (1.7) 22 (18.5)
Tetracycline 14 (11.8) 39 (32.8) 66 (55.4)
ach primer, 100M of each deoxynucleotide trifosfate (dATP,
GTP, dCTP, dTTP) and 1.5U of Taq polimerase (Invitrogen – São
aulo, Brazil). The sequences of primers used were: GATCG-
ATTGGAGAACCAGA and ATTTCTGACCGCATTTCCAT.30The
eaction was carried as follows: initial denaturation at 94 ◦C
or 5minutes; followed by 30 cycles of 94 ◦C for 1minute, 54 ◦C
or 1minute, 72 ◦C for 1 minute; and ﬁnal extension of 72 ◦C for
minutes. A PCR product of 501pb was expected. Acinetobac-
er spp. strain A 29009 producing OXA-23 was used as positive
ontrol for the ampliﬁcation experiments.
esults
ntimicrobial susceptibility proﬁlesigh rates of resistance were observed among isolates stud-
ed. Resistance rates ≥ 70% were observed for seven of the 12
ntimicrobial agents tested (Table 1). The highest resistance
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rate was observed for ciproﬂoxacin (86.6%), followed by
cefepime (82.3%). The percentages for carbapenems were also
elevated; 71.4% for imipenem and 69.7%, for meropenem.
The isolates showed the highest susceptibility rates to
amikacin, followed by tetracycline and gentamicin (58.8%,
55.4%, and 42.9%, respectively). Of notice, a relatively high
rate of intermediate resistance was observed for tetracycline
(32.8%) and ampicillin/sulbactam (17.7%).
IMP-R strains were isolated throughout the entire study
period and showed more elevated resistance rates to other
antimicrobials than isolates susceptible to this antimicrobial
(Fig. 1). Among IMP-R isolates, the highest susceptibility rate
was also observed for amikacin (60%).
Most carbapenem resistant isolates were recovered from
patients hospitalized at the ICU (80%; 68/85), and were recov-
ered mostly from the inferior respiratory tract, (n = 35; 41.2%),
followed by blood (n=21; 25.7%), urine (n=11; 12.9%), and
catheter tip (n=9; 10.6%).
Detection of carbapenemase production and blaOXA-23
The Modiﬁed Hodge Test results revealed carbapenemase pro-
duction among 76 (89.4%) of the 85 IMP-R Acinetobacter isolates
analyzed (Fig. 2).
According to results obtained by PCR, 81 (95.4%) of the 85
IMP-R isolates carried the blaOXA-23 gene (Fig. 3).
Six isolates carrying blaOXA-23 showed negative results for
modiﬁed Hodge Test. Conversely, one isolate was positive for
this phenotypic test, but the presence of blaOXA-23 was not
detected. One of the two isolates that were susceptible to
meropenem and resistant to imipenem carried the blaOXA-23
gene.
DiscussionAll isolates evaluated in this study have been identiﬁed as
belonging to the A. baumanni-complex by the automated sys-
tem. However, it is well established that this method is not
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Fig. 2 – Modiﬁed Hodge Test results for Acinetobacter spp.
clinical isolates. Positive results are indicated with an
arrow. C+, positive control; IMP, imipenem disk; 1570, 1586,
and 1719 are imipenem-resistant Acinetobacter spp.
suitable to distinguish between A. baumannii and other species
such as Acinetobacter pitii, Acinetobacter nosocomialis, and Acine-
tobacter calcoaceticus.36 The presence of blaOXA-51 in all isolates
was also investigated, with positive results (data not shown).
Although blaOXA-51 detection has been pointed out as a sim-
ple and reliable way of identifying A. baumannii, this gene has
also been found in A. nosocomialis, jeopardizing this presump-
tive bacterial identiﬁcation at the species level.37,38 For the
abovementioned reasons, bacterial identiﬁcation results are
expressed only at the genus level in this study.
High resistance rates were observed for most of the antimi-
crobials agents studied, including carbapenems, and even
more elevated rates were observed among IMP-R isolates.
Antimicrobial resistance considerably restricts the avail-
able treatment options, especially resistance to carbapenem,
which is considered to be the ﬁrst option to treat severe infec-
tions due to Acinetobacter spp.Modiﬁed Hodge Test results showed good correlation with
PCR (96.2%), since only six blaOXA-23-positive isolates could not
be detected using the phenotypic methodology, suggesting
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Fig. 3 – Detection of blaOXA-23-like genes in Acinetobacter
spp. clinical isolates. Lines 1 and 21: 1 Kb Plus DNA Ladder;
line 2: blaOXA-23 positive control; line 3: blaOXA-23 negative
control; lines 4-14 and 16-19: isolates carrying blaOXA-23;
line 15: isolate not carrying blaOXA-23; line 20: reaction
control.12;16(6):521–526
that this phenotypic technique is appropriate for screening
Acinetobacter spp. isolates producing such carbapenemases.
These results were consistent with those of Yang et al, which
observed 100% positivity in Modiﬁed Hodge Test among A.
baumannii strains that were IMP-R and OXA-23 producers.20
Recently, researchers from Rio de Janeiro pointed out that
87.6% of IMP-R isolates carrying blaOXA-23 were detected as
carbapenemase producers by the Modiﬁed Hodge Test.24
In the present study, one isolate showing positive Mod-
iﬁed Hodge Test result did not carry the blaOXA-23 gene,
which could suggest either a false-positive phenotypic result
or the presence of another carbapenemase type. Metallo-
-lactamases may be involved in carbapenem resistance
phenotype among Acinetobacter spp., although less frequently
than class D enzymes. In addition, coproduction of metallo-
beta-lactamases and oxacilinases has been described in
Acinetobacter spp. In this study, phenotypic screening tests
were conducted to assess the production of metallo--
lactamases,39 although no isolate showed positive results
(data not shown). Thus, the mechanism involved in car-
bapenem resistance in the abovementioned isolate remains
to be elucidated.40,41
A high frequency of blaOXA-23 (95.4%) was observed among
IMP-R isolates analyzed. This result implies that production
of OXA-23-like enzymes may be an important mechanism of
carbapenem resistance among isolates present in the hospital
studied.
The detection ofA. baumanniiproducingOXA-23 is frequent
in many countries, suggesting a worldwide dissemination
of this enzyme.21 According to Kempf and Rolain, Europe,
Singapore, Australia, the USA, Algeria, Egypt, Libya, South
Africa, Thailand, Tunisia, Iraq, and French Polynesia reported
either nosocomial outbreaks or sporadic cases of Acinetobacter
producing OXA-23.42 In Asia, the most prevalent dissemi-
nated class D enzyme amongst A. baumannii in China and
Korea is OXA-23.43 In Latin America, OXA-23 was identi-
ﬁed in A. baumannii isolates from Argentina, Colombia, and
Brazil.30 In Brazil, OXA-23-like enzymes have been identiﬁed
as one of the major carbapenem resistance mechanism in
Acinetobacter spp.25,28–32,44,45 In Rio de Janeiro, a surveillance
study conducted in eight hospitals showed a wide dissemi-
nation of isolates producing such carbapenemases. In Niterói,
the occurrence of A. baumannii strains carrying blaOXA-23 has
already been reported at a public hospital, however, at a
smaller rate (15%) than found in the present study.24,27
In conclusion, early detection of IMP-R Acinetobacter iso-
lates, and of the corresponding mechanism of resistance is
extremely important to prevent their dissemination through-
out the hospital environment. It could be beneﬁcial to
routinely perform the surveillance of isolates producing car-
bapenemases in the hospital investigated. In addition, strict
control measures, as well as prudent utilization of antimicro-
bials agents should be continuously promoted.Conﬂict of interest
All authors declare to have no conﬂict of interest.
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